JP2017526916A - 癌の診断 - Google Patents

癌の診断 Download PDF

Info

Publication number
JP2017526916A
JP2017526916A JP2017507713A JP2017507713A JP2017526916A JP 2017526916 A JP2017526916 A JP 2017526916A JP 2017507713 A JP2017507713 A JP 2017507713A JP 2017507713 A JP2017507713 A JP 2017507713A JP 2017526916 A JP2017526916 A JP 2017526916A
Authority
JP
Japan
Prior art keywords
cancer
sample
patient
oncoprotein
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017507713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526916A5 (enExample
Inventor
ツォン，チ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2017526916A publication Critical patent/JP2017526916A/ja
Publication of JP2017526916A5 publication Critical patent/JP2017526916A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017507713A 2014-08-13 2015-08-13 癌の診断 Withdrawn JP2017526916A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201404895X 2014-08-13
SG10201404895XA SG10201404895XA (en) 2014-08-13 2014-08-13 Diagnosis
PCT/SG2015/050259 WO2016024918A1 (en) 2014-08-13 2015-08-13 Diagnosis of cancer

Publications (2)

Publication Number Publication Date
JP2017526916A true JP2017526916A (ja) 2017-09-14
JP2017526916A5 JP2017526916A5 (enExample) 2018-09-13

Family

ID=55304429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507713A Withdrawn JP2017526916A (ja) 2014-08-13 2015-08-13 癌の診断

Country Status (6)

Country Link
US (1) US20170234880A1 (enExample)
EP (1) EP3189333A4 (enExample)
JP (1) JP2017526916A (enExample)
CN (1) CN106716132A (enExample)
SG (2) SG10201404895XA (enExample)
WO (1) WO2016024918A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030626A1 (ja) * 2020-08-06 2022-02-10 株式会社Ｌｓｉメディエンス 膀胱癌診断方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10874610B2 (en) 2016-10-19 2020-12-29 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
CN107058556A (zh) * 2017-05-09 2017-08-18 大连海事大学 一种用于评估硫丹促癌风险的方法
CN110613727B (zh) * 2017-12-11 2022-06-21 浙江大学 NK细胞外泌体hsa-miR-9502在抗菌中的应用
CN110531082A (zh) * 2018-05-25 2019-12-03 国家纳米科学中心 用于乳腺癌检测及分子分型的外泌体检测装置和应用
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
CN118376789B (zh) * 2024-06-25 2024-09-13 南昌大学第一附属医院 一种用于诊断肺癌的检测试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848742A1 (en) * 2005-01-28 2007-10-31 Attogen, Inc. Anti-prl-3 antibodies and methods of use thereof
DK3360571T3 (da) * 2007-05-03 2021-01-04 Agency For Science Tech And Research Astarstar Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
CN108434440B (zh) * 2011-09-06 2022-08-23 新加坡科技研究局 多肽疫苗

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030626A1 (ja) * 2020-08-06 2022-02-10 株式会社Ｌｓｉメディエンス 膀胱癌診断方法
JPWO2022030626A1 (enExample) * 2020-08-06 2022-02-10

Also Published As

Publication number Publication date
WO2016024918A1 (en) 2016-02-18
EP3189333A4 (en) 2018-04-18
SG10201404895XA (en) 2016-03-30
SG11201701076TA (en) 2017-03-30
EP3189333A1 (en) 2017-07-12
CN106716132A (zh) 2017-05-24
US20170234880A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
US11219645B2 (en) Tumor infiltrating lymphocytes for treatment of cancer
JP2017526916A (ja) 癌の診断
US8871450B2 (en) Biomarker for colorectal cancer
ES2877757T3 (es) Tratamiento terapéutico de cáncer de mama basado en el estado de c-MAF
JP2018138058A (ja) 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
JP2018538263A (ja) 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体の組合せを用いる肺癌の処置法
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
KR20130055647A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
JP6316498B2 (ja) Ｃｋａｐ４を標的分子とした抗腫瘍剤
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
JP2018516870A (ja) ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
JP2020040959A (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
CN107531789B (zh) 用于抗血管新生和标靶癌症治疗的抗vegfr2人类抗体
JP2022519649A (ja) がんの診断および治療方法
CN103238069B (zh) 肺癌和结直肠癌中的bard1同工型及其应用
JP2014501918A (ja) ベバシズマブ併用療法のためのマーカーとしてのａｇｔｒ１
CA3112382A1 (en) Methods for treating pancreatitis
WO2022154037A1 (ja) がんの予後バイオマーカー
CN113677994B (zh) 用于评估t细胞功能和预测对疗法的应答的方法和药剂
JP6341859B2 (ja) がんマーカーおよびその用途
CN111656194B (zh) Tnbc划分和治疗的方法和组合物
JP2025537128A (ja) 非小細胞肺癌の検出及び治療の方法
WO2025075127A1 (ja) がんのバイオマーカー及び抗体治療
JP2025172327A (ja) がんのバイオマーカー、それに対する抗体、抗体を用いたがん患者の予後の予測方法、および、がんの検出方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180802

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190326